What is EnsiliTech?
EnsiliTech is a specialized biotechnology firm focused on the development of advanced storage solutions for the pharmaceutical industry. By leveraging its patented Ensilication technology, the company effectively eliminates the reliance on energy-intensive cold-chain infrastructure. This innovation allows for the protection of vaccines, antibodies, and enzymes in a temperature-stable silica matrix, significantly reducing logistical costs and environmental impact while ensuring the integrity of life-saving medical products during transit and storage.
How much funding has EnsiliTech raised?
EnsiliTech has raised a total of $7.5M across 2 funding rounds:
Other Financing Round
$1.4M
Seed
$6M
Other Financing Round (2023): $1.5M with participation from UK Research & Innovation, QantX, Fink Family Law Offices, Science Angel Syndicate, and Elbow Beach Capital
Seed (2025): $6M led by Eos Advisory, Fink Family Law Offices, Calculus Capital, and QantX
Key Investors in EnsiliTech
Eos Advisory
A Scottish investment firm focused on bridging innovation with global opportunities by investing in and commercializing science and technology, with a specific emphasis on quality of life and environmental sustainability.
QantX
A venture capital firm dedicated to transforming the underfunded spinout landscape in the South West UK by investing in high-impact innovations within the technology and science-based sectors.
Calculus Capital
A London-based investment manager specializing in tax-efficient growth capital for UK smaller companies, focusing on high-growth technology, healthcare, and creative industries.
What's next for EnsiliTech?
With this latest round of financing, EnsiliTech is well-positioned to accelerate the commercialization of its silica-based stabilization platform. The strategic focus will likely shift toward expanding manufacturing capabilities and forging partnerships with global pharmaceutical distributors to integrate Ensilication into existing supply chains. As the company transitions into this next phase of growth, the emphasis will remain on validating the technology across diverse biological applications and securing regulatory milestones that will solidify its position as a leader in the biopharmaceutical logistics space.
See full EnsiliTech company page
